On in vivo cell therapy quest, Takeda-backed Ensoma buys a CRISPR upstart and bags $85M
Cell therapy biotech Ensoma made an all-stock acquisition of Danish CRISPR technology upstart Twelve Bio, and also raised an $85 million Series B.
The Boston biotech will use the proceeds to bring its lead oncology program into the clinic, with the goal of targeting hematopoietic stem cells with a one-time, off-the-shelf therapy, CEO Emile Nuwaysir told Endpoints News. Nuwaysir joined the Takeda-allied biotech in the fall of 2021, after leading Parkinson’s-focused BlueRock to an exit to Bayer. Ensoma had remained relatively quiet from his arrival until the financing and M&A disclosure on Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.